Planning a pregnancy on Ozempic or Wegovy: what the science says

The short version

The American Diabetes Association and the Endocrine Society recommend stopping GLP-1 medications at least two months before trying to conceive. Human pregnancy data is still limited, so the safest approach is to plan the timing, use reliable contraception until then, and rebuild your nutrition during the gap.

If you take a GLP-1 medication like Ozempic or Wegovy and you are thinking about having a baby, the first question is usually about timing. Semaglutide, the drug in both, stays in your system for weeks, which is why guidelines want it cleared well before conception. The reasons behind the two-month rule, and what happens if a pregnancy arrives sooner, are worth understanding before you make the call with your prescriber.

How long before pregnancy should you stop a GLP-1?

The American Diabetes Association and the Endocrine Society both recommend stopping GLP-1 medications at least two months before you attempt pregnancy. The European Society of Endocrinology gives the same two-month guidance for semaglutide. These drugs have a long half-life, so the window is meant to clear the medication from your body before conception.

Here is the honest gap. The exact ideal washout time is not settled. The 2026 review in the American Journal of Preventive Cardiology that gathers this evidence together calls the optimal duration of discontinuation "unknown," and notes the observational data behind it conflicts. Two months is the current floor, not a precise finish line.

Contraception is part of the plan

Because roughly 40% of pregnancies in the United States are unplanned, accidental exposure is a real possibility for anyone of child-bearing age on a GLP-1. Guidelines advise using effective contraception the entire time you take one, not just when you decide to stop.

Tirzepatide, the drug in Mounjaro and Zepbound, adds a wrinkle. It slows stomach emptying enough to reduce how well the body absorbs oral birth control. If you start tirzepatide or raise your dose, use a second, non-oral form of contraception until you have been at your maintenance dose for at least four weeks.

What if you conceive while still taking a GLP-1?

First, call your prescriber rather than panic. The cohort studies so far have not shown a clear rise in major birth defects, though every one of them comes with real limits.

• Cesta and colleagues (2024) looked at more than 50,000 pregnancies in women with type 2 diabetes and found no increase in major congenital malformations with GLP-1 medications compared with insulin.
• Dao and colleagues (2024) followed 168 pregnancies with GLP-1 exposure. Birth defect rates were comparable to diabetic and overweight controls, and most pregnancies ended in live births.
• A Danish study by Kolding and colleagues (2025) tracked 32 pregnancies with first-trimester semaglutide exposure. Newborn outcomes were largely reassuring, but the researchers saw higher rates of preterm birth, large-for-gestational-age infants, and newborn low blood sugar, effects that may be driven by the underlying diabetes rather than the drug.
• Hanif and colleagues (2025) studied 3,652 women who used a GLP-1 within a year before and a month after pregnancy and reported a possible increase in fetal anomalies, with no rise in maternal deaths.

The signal is mixed and the numbers are small. FDA labels for semaglutide, tirzepatide, exenatide, albiglutide, and lixisenatide all cite embryo-fetal toxicity seen in animal studies, which is why the official position is to avoid these drugs in pregnancy. For a closer look at the accidental-exposure question, see our article on first-trimester semaglutide exposure and the counseling gap.

Does stopping early actually help the pregnancy?

This is where the evidence gets genuinely interesting, and genuinely unsettled. Some data suggests that losing weight and improving metabolic health before conception may lower certain pregnancy risks.

Imbroane and colleagues (2025) studied 4,267 women with obesity or type 2 diabetes who used a GLP-1 before conceiving and found lower rates of gestational diabetes and high blood pressure disorders of pregnancy. Pondugula and colleagues (2025) reported similar results in 243 patients, with lower odds of pregnancy-related high blood pressure, an adjusted odds ratio of about 0.51 to 0.52.

The picture is not one-sided, though. Maya and colleagues (2024), in a much larger sample of 149,790 women, found GLP-1 use was associated with more gestational weight gain and higher risk of gestational diabetes, high blood pressure disorders, and preterm delivery. Two large studies, opposite conclusions. Researchers are still investigating why, and confounding by the underlying obesity and diabetes is the likely explanation. This is not settled science, so treat any "stop early to protect the pregnancy" claim with caution.

The washout window is a nutrition window

The two-month gap before conception is not dead time. It is a chance to rebuild the nutrient stores that a GLP-1 can quietly drain, right when your body is about to need them most.

Appetite suppression is the whole point of these drugs, but eating far less also means taking in fewer vitamins and minerals. Nutrient deficiency on GLP-1 medications tends to worsen over time, nearly doubling between month 6 and month 12 of use in one analysis. Two nutrients matter most before pregnancy. Folate lowers the risk of neural tube defects and should be topped up before conception, not after. Iron matters because pregnancy demands a lot of it. Vitamin B12 and vitamin D are also worth checking, since low intake is common on these medications.

Muscle is the other concern. Roughly 20% to 40% of the weight lost on GLP-1 medications is lean mass, not fat. Muscle loss on Ozempic and similar drugs can leave you less prepared for the metabolic demands of pregnancy, which is why protein intake and resistance exercise matter during and after the washout. Most GLP-1 users fall short on protein already.

Ask your prescriber about testing for common gaps and repleting them before you conceive. This nutrient-gap problem is exactly what GLP-1 Shield is built around. For the specifics, see our guides on which vitamins to take and monitor on GLP-1 and muscle loss and protein intake.

After the baby: postpartum and breastfeeding

Once the baby arrives, two questions come up. When can you restart, and is it safe while breastfeeding?

On restarting, there is very little to go on. The only trial of GLP-1 therapy in postpartum women randomized 153 participants with prior gestational diabetes to metformin with or without liraglutide. At 84 weeks, the group that added liraglutide had greater weight loss and better blood sugar and cholesterol control. Beyond that single trial, restart timing is individualized, weighing your metabolic needs, breastfeeding status, and family planning with your doctor.

On breastfeeding, the current recommendation is to avoid GLP-1 medications, even though the limited data looks reassuring. A pharmacokinetic study of semaglutide in 8 women found no detectable drug in breast milk at 0, 12, or 24 hours after a dose, and the protein-bound structure of these drugs limits how much passes into milk. The caution is less about the drug crossing over and more about calories. These medications cut appetite, and milk production needs enough calories, protein, and healthy fats. Early findings are limited, so the safe default is to hold off until more human lactation data exists.

Main points

• The American Diabetes Association and Endocrine Society recommend stopping GLP-1 medications at least two months before trying to conceive.
• Use effective contraception on a GLP-1, and add a second non-oral method for four weeks after starting or raising tirzepatide.
• First-trimester exposure studies so far show no clear rise in major birth defects, but the samples are small and the evidence is mixed.
• The washout window is the time to replete folate, iron, vitamin B12, vitamin D, and protein before pregnancy.
• Breastfeeding guidance is to avoid GLP-1 medications for now, mainly over calorie and milk-supply concerns rather than proven drug transfer.

General information, not medical advice. GLP-1 medications are prescription-only, and decisions about stopping, restarting, or planning a pregnancy should be made with your own doctor. Evidence current as of September 2026.

Frequently asked questions

How long before pregnancy should I stop Ozempic?

The American Diabetes Association and the Endocrine Society recommend stopping GLP-1 medications, including Ozempic, at least two months before you try to conceive. The two-month window lets the long-acting drug clear before conception. The exact ideal duration is not settled, so confirm the timing with your prescriber.

Can you get pregnant while taking Ozempic?

Yes. Ozempic does not prevent pregnancy, and about 40% of US pregnancies are unplanned, so accidental exposure happens. Anyone of child-bearing age on a GLP-1 should use effective contraception, and add a second non-oral method for four weeks after starting or raising tirzepatide, which can reduce oral contraceptive absorption.

Is it safe to breastfeed while taking Wegovy?

Current guidance is to avoid GLP-1 medications like Wegovy while breastfeeding. A small study of semaglutide in 8 women found no detectable drug in breast milk, but human lactation data is limited. The bigger concern is that reduced appetite may lower the calories and protein needed for milk supply.

Does stopping a GLP-1 before pregnancy lower gestational diabetes risk?

The evidence is mixed. Imbroane and colleagues (2025) found lower rates of gestational diabetes in 4,267 women who used a GLP-1 before conceiving, while Maya and colleagues (2024) found higher risk in 149,790 women. Researchers are still investigating, and the underlying obesity and diabetes likely explain part of the difference.